Mesa Laboratories MLAB Clinical Genomics — Cost Of Goods And Services Sold Depreciation

Other segment segments

Similar metrics at other companies

CWCOServices — Cost Of Goods And Services Sold Depreciation

$107.53K+18.7%

BIOClinical Diagnostics — Cost of goods sold

$181.8M+1.5%

BIOClinical Diagnostics — Depreciation, Depletion and Amortization

$22.6M+7.1%

THAll Other Segments — Cost Of Goods And Services Sold Depreciation

$868K-1.1%

ASTHCare Delivery — Cost Of Goods And Services Sold Depreciation And Amortization

$1.12M+109%

FTREClinical Services Segment — D&A

$5.2M+4.0%

Questions, answered.

What is Mesa Laboratories's clinical genomics — cost of goods and services sold depreciation?

Mesa Laboratories (MLAB) reported clinical genomics — cost of goods and services sold depreciation of $127K in Q1 2026.

How has Mesa Laboratories's clinical genomics — cost of goods and services sold depreciation changed year-over-year?

Mesa Laboratories's clinical genomics — cost of goods and services sold depreciation decreased by 23.5% year-over-year, from $166K to $127K.

What is the long-term trend for Mesa Laboratories's clinical genomics — cost of goods and services sold depreciation?

Over 2 years (2024 to 2026), Mesa Laboratories's clinical genomics — cost of goods and services sold depreciation has grown at a -21.5% compound annual growth rate (CAGR), from $937K to $578K.

What does clinical genomics — cost of goods and services sold depreciation mean?

This reflects the portion of depreciation expense allocated to the production of goods and services within the Clinical Genomics segment. It represents the systematic allocation of the cost of tangible assets used in the manufacturing process over their useful lives.